Balance of brain motor pathways disrupted in Parkinson’s: Study
Depletion of the neurotransmitter dopamine, which occurs in people with Parkinson’s disease, disrupts the balance of motor pathways in…
Articles by Steve Bryson, PhD
Researchers discover new cellular mechanisms in Parkinson’s disease
Clumps of RNA-binding proteins have been discovered in the nucleus of nerve cells derived from people with Parkinson’s disease,…
Buntanetap found to halt cognitive decline in early Parkinson’s trial
Six months of once-daily buntanetap halted cognitive decline among people in the early stages of Parkinson’s disease, and…
GT-02287 aids motor, cognitive function in GBA1 Parkinson’s mice
Once-daily treatment with Gain Therapeutics‘ GT-02287 rescued motor function and cognitive performance in a mouse model of Parkinson’s…
Genetic variants tied to mortality, motor progression in Parkinson’s
Six genetic variants associated with mortality and motor progression have been discovered in people with Parkinson’s disease. These newly…
IRL757, potential 1st apathy treatment, begins Phase 1 testing
Dosing has begun in a Phase 1 clinical trial evaluating the safety and efficacy of IRL757, an oral candidate for…
National Plan to End Parkinson’s Act approved in US Congress
The U.S. Senate has joined the House of Representatives in approving The National Plan to End Parkinson’s Act, the…
Emotional processing tied to facial recognition in Parkinson’s: Study
Deficits in emotional processing, rather than impaired ability to simulate facial expressions, likely explain problems Parkinson’s disease patients encounter…
Alterations in epigenetic marks found in Parkinson’s patients: Study
Potential environmentally-driven alterations in certain epigenetic marks — DNA modifications that control gene activity — were detected in the blood…
Add-on tavapadon eases symptoms in late Parkinson’s, data show
Six months of daily tavapadon, as an oral add-on therapy to standard levodopa, significantly increased on time without troublesome…